Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Advanced oxidation protein products contribute to chronic kidney disease-induced muscle atrophy by inducing oxidative stress via CD36/NADPH oxidase pathway.
Kato H, Watanabe H, Imafuku T, Arimura N, Fujita I, Noguchi I, Tanaka S, Nakano T, Tokumaru K, Enoki Y, Maeda H, Hino S, Tanaka M, Matsushita K, Fukagawa M, Maruyama T. Kato H, et al. Among authors: matsushita k. J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):1832-1847. doi: 10.1002/jcsm.12786. Epub 2021 Oct 2. J Cachexia Sarcopenia Muscle. 2021. PMID: 34599649 Free PMC article.
Advanced Oxidation Protein Products Contribute to Renal Tubulopathy via Perturbation of Renal Fatty Acids.
Imafuku T, Watanabe H, Satoh T, Matsuzaka T, Inazumi T, Kato H, Tanaka S, Nakamura Y, Nakano T, Tokumaru K, Maeda H, Mukunoki A, Takeo T, Nakagata N, Tanaka M, Matsushita K, Tsuchiya S, Sugimoto Y, Shimano H, Fukagawa M, Maruyama T. Imafuku T, et al. Among authors: matsushita k. Kidney360. 2020 Jun 3;1(8):781-796. doi: 10.34067/KID.0000772019. eCollection 2020 Aug 27. Kidney360. 2020. PMID: 35372949 Free PMC article.
Effect of a Ferric Citrate Formulation, a Phosphate Binder, on Oxidative Stress in Chronic Kidney Diseases-Mineral and Bone Disorder Patients Receiving Hemodialysis: A Pilot Study.
Tanaka M, Miyamura S, Imafuku T, Tominaga Y, Maeda H, Anraku M, Yamasaki K, Kadowaki D, Ishima Y, Watanabe H, Okuda T, Itoh K, Matsushita K, Fukagawa M, Otagiri M, Maruyama T. Tanaka M, et al. Among authors: matsushita k. Biol Pharm Bull. 2016;39(6):1000-6. doi: 10.1248/bpb.b15-01021. Biol Pharm Bull. 2016. PMID: 27251502 Free article.
Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction.
Enoki Y, Watanabe H, Arake R, Fujimura R, Ishiodori K, Imafuku T, Nishida K, Sugimoto R, Nagao S, Miyamura S, Ishima Y, Tanaka M, Matsushita K, Komaba H, Fukagawa M, Otagiri M, Maruyama T. Enoki Y, et al. Among authors: matsushita k. J Cachexia Sarcopenia Muscle. 2017 Oct;8(5):735-747. doi: 10.1002/jcsm.12202. Epub 2017 Jun 12. J Cachexia Sarcopenia Muscle. 2017. PMID: 28608457 Free PMC article.
Parathyroid hormone contributes to the down-regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF-κB signaling pathway in secondary hyperparathyroidism.
Watanabe H, Sugimoto R, Ikegami K, Enoki Y, Imafuku T, Fujimura R, Bi J, Nishida K, Sakaguchi Y, Murata M, Maeda H, Hirata K, Jingami S, Ishima Y, Tanaka M, Matsushita K, Komaba H, Fukagawa M, Otagiri M, Maruyama T. Watanabe H, et al. Among authors: matsushita k. Biochem Pharmacol. 2017 Dec 1;145:192-201. doi: 10.1016/j.bcp.2017.08.016. Epub 2017 Aug 24. Biochem Pharmacol. 2017. PMID: 28843775
A synthetic retinoic acid receptor agonist Am80 ameliorates renal fibrosis via inducing the production of alpha-1-acid glycoprotein.
Watanabe H, Bi J, Murata R, Fujimura R, Nishida K, Imafuku T, Nakamura Y, Maeda H, Mukunoki A, Takeo T, Nakagata N, Kurauchi Y, Katsuki H, Tanaka M, Matsushita K, Fukagawa M, Maruyama T. Watanabe H, et al. Among authors: matsushita k. Sci Rep. 2020 Jul 10;10(1):11424. doi: 10.1038/s41598-020-68337-z. Sci Rep. 2020. PMID: 32651445 Free PMC article.
2,408 results